KR20210074329A - 매크로사이클릭 플루 엔도뉴클레아제 억제제 - Google Patents
매크로사이클릭 플루 엔도뉴클레아제 억제제 Download PDFInfo
- Publication number
- KR20210074329A KR20210074329A KR1020217013939A KR20217013939A KR20210074329A KR 20210074329 A KR20210074329 A KR 20210074329A KR 1020217013939 A KR1020217013939 A KR 1020217013939A KR 20217013939 A KR20217013939 A KR 20217013939A KR 20210074329 A KR20210074329 A KR 20210074329A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- synthesis
- phenyl
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C([C@@](C=CCOc1cccc(CSc2c3cccc2)c1[C@@]3N(C1)N(C=CC2=O)C3=C2O)N1C3=O)(F)F Chemical compound *C([C@@](C=CCOc1cccc(CSc2c3cccc2)c1[C@@]3N(C1)N(C=CC2=O)C3=C2O)N1C3=O)(F)F 0.000 description 1
- SKRIAHTVQOTPGA-NRFANRHFSA-N CN(CN([C@@H](c1ccccc1)c(cccc1F)c1OCC1CC1)N(C=CC1=O)C2=C1O)C2=O Chemical compound CN(CN([C@@H](c1ccccc1)c(cccc1F)c1OCC1CC1)N(C=CC1=O)C2=C1O)C2=O SKRIAHTVQOTPGA-NRFANRHFSA-N 0.000 description 1
- SKRIAHTVQOTPGA-OAQYLSRUSA-N CN(CN([C@H](c1ccccc1)c(cccc1F)c1OCC1CC1)N(C=CC1=O)C2=C1O)C2=O Chemical compound CN(CN([C@H](c1ccccc1)c(cccc1F)c1OCC1CC1)N(C=CC1=O)C2=C1O)C2=O SKRIAHTVQOTPGA-OAQYLSRUSA-N 0.000 description 1
- CMYIBNONEAEEOH-OAQYLSRUSA-N COc1c([C@@H](c2ccccc2)N(CN(CC2CC2)C2=O)N(C=CC3=O)C2=C3O)cccc1F Chemical compound COc1c([C@@H](c2ccccc2)N(CN(CC2CC2)C2=O)N(C=CC3=O)C2=C3O)cccc1F CMYIBNONEAEEOH-OAQYLSRUSA-N 0.000 description 1
- HRDLWGGBVSGNPW-JVNGFTGRSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3Cl)c3OC/C=C/C3(CC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3Cl)c3OC/C=C/C3(CC3)N1C2=O HRDLWGGBVSGNPW-JVNGFTGRSA-N 0.000 description 1
- COACKJLPCHZWGL-FQEVSTJZSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3F)c3OCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3F)c3OCCCCN1C2=O COACKJLPCHZWGL-FQEVSTJZSA-N 0.000 description 1
- UJAUDCRLUJZFIZ-LZJOCLMNSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3cccc(F)c3OC[C@@H](C3)[C@H]3CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3cccc(F)c3OC[C@@H](C3)[C@H]3CN1C2=O UJAUDCRLUJZFIZ-LZJOCLMNSA-N 0.000 description 1
- MCZPJPITOMHTBN-XQQSMPNESA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3C(F)F)c(ccc(F)c3F)c3OC/C=C\CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3C(F)F)c(ccc(F)c3F)c3OC/C=C\CN1C2=O MCZPJPITOMHTBN-XQQSMPNESA-N 0.000 description 1
- IHJOLWLZLSLMKI-JTSKRJEESA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OCCC[C@@H](C(F)F)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OCCC[C@@H](C(F)F)N1C2=O IHJOLWLZLSLMKI-JTSKRJEESA-N 0.000 description 1
- GWVBHJHJCJICDK-LTETZXIYSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SCc3ccc4)c3c4OC/C=C/[C@H](C(F)F)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SCc3ccc4)c3c4OC/C=C/[C@H](C(F)F)N1C2=O GWVBHJHJCJICDK-LTETZXIYSA-N 0.000 description 1
- JOJNCSJVVGWKCZ-QAOXHIRNSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(ccc(F)c3F)c3OC/C=C/C3(CCC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(ccc(F)c3F)c3OC/C=C/C3(CCC3)N1C2=O JOJNCSJVVGWKCZ-QAOXHIRNSA-N 0.000 description 1
- HRDLWGGBVSGNPW-AWGFCZPBSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3Cl)c3OC/C=C/C3(CC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3Cl)c3OC/C=C/C3(CC3)N1C2=O HRDLWGGBVSGNPW-AWGFCZPBSA-N 0.000 description 1
- COACKJLPCHZWGL-HXUWFJFHSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3F)c3OCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3F)c3OCCCCN1C2=O COACKJLPCHZWGL-HXUWFJFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744060P | 2018-10-10 | 2018-10-10 | |
| US62/744,060 | 2018-10-10 | ||
| PCT/IB2019/058591 WO2020075080A1 (en) | 2018-10-10 | 2019-10-09 | Macrocyclic flu endonuclease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210074329A true KR20210074329A (ko) | 2021-06-21 |
Family
ID=68242803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217013939A Ceased KR20210074329A (ko) | 2018-10-10 | 2019-10-09 | 매크로사이클릭 플루 엔도뉴클레아제 억제제 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11312727B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3864020A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022512676A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210074329A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113195502A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019359539A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3115792A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004182A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202035424A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020075080A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021191872A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Biopharma, Inc. | Heteroaryl-substituted macrocyclic flu endonuclease inhibitors |
| CN113444010B (zh) * | 2020-03-28 | 2023-09-05 | 南京正大天晴制药有限公司 | 一种沙芬酰胺有关物质的制备方法 |
| JP7407976B2 (ja) * | 2020-05-21 | 2024-01-04 | シーセン ファーマシューティカル カンパニー リミテッド | 縮合環誘導体及びその薬学的用途 |
| WO2021249522A1 (zh) * | 2020-06-12 | 2021-12-16 | 上海翰森生物医药科技有限公司 | 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| EP4384178A4 (en) * | 2021-08-11 | 2025-07-02 | Merck Sharp & Dohme Llc | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLUENZA |
| CN118317964A (zh) * | 2021-11-17 | 2024-07-09 | 辰欣药业股份有限公司 | 一种稠环衍生物的晶型及其制备方法 |
| WO2025015300A2 (en) * | 2023-07-12 | 2025-01-16 | Apac Pharma, Llc | Hepoxilin analogs, methods, uses, and processes for preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8927710B2 (en) * | 2009-06-15 | 2015-01-06 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| DK2620436T3 (en) * | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| SI3030549T1 (sl) * | 2013-09-12 | 2019-08-30 | Janssen Biopharma, Inc. | Spojine piridazinona in njihove uporabe |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
-
2019
- 2019-10-09 US US17/284,162 patent/US11312727B1/en active Active
- 2019-10-09 MX MX2021004182A patent/MX2021004182A/es unknown
- 2019-10-09 WO PCT/IB2019/058591 patent/WO2020075080A1/en not_active Ceased
- 2019-10-09 EP EP19787467.0A patent/EP3864020A1/en not_active Withdrawn
- 2019-10-09 KR KR1020217013939A patent/KR20210074329A/ko not_active Ceased
- 2019-10-09 CA CA3115792A patent/CA3115792A1/en active Pending
- 2019-10-09 TW TW108136776A patent/TW202035424A/zh unknown
- 2019-10-09 CN CN201980082149.XA patent/CN113195502A/zh active Pending
- 2019-10-09 AU AU2019359539A patent/AU2019359539A1/en not_active Abandoned
- 2019-10-09 JP JP2021519876A patent/JP2022512676A/ja not_active Withdrawn
-
2022
- 2022-03-15 US US17/694,757 patent/US20230002409A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022512676A (ja) | 2022-02-07 |
| CA3115792A1 (en) | 2020-04-16 |
| US11312727B1 (en) | 2022-04-26 |
| US20230002409A1 (en) | 2023-01-05 |
| EP3864020A1 (en) | 2021-08-18 |
| CN113195502A (zh) | 2021-07-30 |
| AU2019359539A1 (en) | 2021-04-29 |
| MX2021004182A (es) | 2021-09-08 |
| WO2020075080A1 (en) | 2020-04-16 |
| TW202035424A (zh) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210074329A (ko) | 매크로사이클릭 플루 엔도뉴클레아제 억제제 | |
| EP2527007B1 (en) | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | |
| JP5758024B2 (ja) | 化合物 | |
| UA110688C2 (uk) | Біциклічні піридинони | |
| EA020409B1 (ru) | Антагонисты рецептора cgrp | |
| AU2020283361B2 (en) | Benzotriazole derivative | |
| CA2880523A1 (en) | Aryl lactam kinase inhibitors | |
| EP3774741A1 (en) | Antimalarial hexahydropyrimidine analogues | |
| TW202340198A (zh) | 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途 | |
| EP0670317B9 (en) | Epoxycyclohexenedione derivative | |
| CN105008369A (zh) | 人类免疫缺陷病毒复制抑制剂 | |
| EP4291183B1 (en) | Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis | |
| HK40057802A (en) | Macrocyclic flu endonuclease inhibitors | |
| EP2274294B1 (en) | 5-demethoxyfumagillol and derivatives thereof | |
| CN114057769A (zh) | 大环哒嗪类化合物及其用途 | |
| NO300372B1 (no) | Nye <alfa>-mannosidaseinhibitorer | |
| RU2045528C1 (ru) | Способ получения оптически активного производного индолобензохинолина или его фармацевтически приемлемых солей | |
| KR102892606B1 (ko) | 신규 글루코코르티코이드 수용체 효능제 | |
| Haghighi | Asymmetric Allenic Pauson− Khand Reaction to Access Thapsigargin: Influence of a Remote Stereocenter on Stereodifferentiation | |
| JP2024055860A (ja) | 二環性ピリジン誘導体を含有する医薬 | |
| CA3256688A1 (en) | BENZOTRIAZOLE COMPOUND | |
| WO2023009610A1 (en) | Methods for synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone | |
| WO2022215754A1 (ja) | 二環性ピリジン誘導体 | |
| Harnying | Asymmetric synthesis of sultones and sulfonic acid derivatives | |
| JPH03115287A (ja) | トリシクロ化合物およびそれを含む医薬組成物、並びにその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210507 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20221007 Comment text: Request for Examination of Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240924 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20241202 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |